GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Net Margin %

Akari Therapeutics (FRA:CLA) Net Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Akari Therapeutics's Net Income for the three months ended in Sep. 2024 was €-2.61 Mil. Akari Therapeutics's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Akari Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Akari Therapeutics's Net Margin % or its related term are showing as below:


FRA:CLA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

Akari Therapeutics Net Margin % Historical Data

The historical data trend for Akari Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Net Margin % Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akari Therapeutics's Net Margin %

For the Biotechnology subindustry, Akari Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Net Margin % falls into.



Akari Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Akari Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-9.177/0
= %

Akari Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-2.608/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akari Therapeutics  (FRA:CLA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Akari Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics Business Description

Traded in Other Exchanges
Address
22 Boston Wharf Road, Boston, MA, USA, 02210
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).